Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis

Authors
Pae, Chi-UnWang, Sheng-MinHan, ChangsuLee, Soo-JungPatkar, Ashwin A.Masand, Praksh S.Serretti, Alessandro
Issue Date
5월-2015
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Keywords
Vortioxetine; Meta-analysis; Efficacy; Safety; Tolerability; Generalized anxiety disorder
Citation
JOURNAL OF PSYCHIATRIC RESEARCH, v.64, pp.88 - 98
Indexed
SCIE
SSCI
SCOPUS
Journal Title
JOURNAL OF PSYCHIATRIC RESEARCH
Volume
64
Start Page
88
End Page
98
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/93796
DOI
10.1016/j.jpsychires.2015.02.017
ISSN
0022-3956
Abstract
Vortioxetine has a beneficial pharmacological profile for reducing anxiety and depression. Recently, a number of randomized, double-blind, placebo-controlled clinical trials (RCTs) of vortioxetine have been conducted in patients with generalized anxiety disorder (GAD); however, the results from GAD. RCTs are inconsistent. With an extensive search of databases and clinical trial registries, four published short-term RCTs were identified and included in the present meta-analysis. The mean change in total scores on the Hamilton Anxiety Rating Scale (HAMA) from baseline was the primary endpoint. The secondary endpoints included the response and remission rates, as defined by a >= 50% reduction in HAMA total scores and a <= 7 change in the HAMA total score at the end of treatment. In addition, the mean change in the HAMA total score from baseline in the subgroup with a HAMA total score >= 25 at baseline was included. Vortioxetine was significantly more effective than was placebo, with a standardized mean difference (SMD) of -0.118 (95% CIs, -0.203 to -0.033, P = 0.007). In particular, those with severe GAD (HAMA total score >= 25 at baseline) had a significantly greater benefit from vortioxetine than those without (SMD = -0.338, 95% CIs = -0.552 to -0.124, p = 0.002). The odds ratios (ORs) for vortioxetine for response and remission were 1.221 (95% CIs, 1.027 to 1.452, P = 0.024) and 1.052 (95% CIs, 0.853 to 1.296, P = 0.637), respectively. Discontinuation due to adverse events (AEs) (OR = 1.560, 1.006 to 2.419, p = 0.047) was marginally higher in vortioxetine than placebo treatment, whereas discontinuation due to any reason (OR = 0.971, 0.794 to 1.187, p = 0.771) and inefficacy (OR = 0.687, 0.380 to 1.243, p = 0.215) were not significantly different among treatment groups. Although our results suggest that vortioxetine may have a potential as an another treatment option for GAD (especially for severe GAD), they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of RCTs. (C) 2015 Elsevier Ltd. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Han, Chang su photo

Han, Chang su
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE